Sepsis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Sepsis - Pipeline Review, H2 2015, provides an overview of the Sepsiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Sepsis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sepsis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC @http://www.idatainsights.com/reports-landing-page.php?id=124189/sepsis-pipeline-review-h2-2015
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landing-page.php?id=124189/sepsis-pipeline-review-h2-2015
Table of Contents
Table of Contents
2 List of Tables
6 List of Figures
8 Global Markets Direct Report Coverage
8 Sepsis Overview
9 Therapeutics Development
10 Pipeline Products for Sepsis - Overview
10 Pipeline Products for Sepsis - Comparative Analysis
11 Sepsis - Therapeutics under Development by Companies
12 Sepsis - Therapeutics under Investigation by Universities/Institutes
17 Sepsis - Pipeline Products Glance
19 Late Stage Products
19 Clinical Stage Products
20 Early Stage Products
21 Unknown Stage Products
22 Sepsis - Products under Development by Companies
23 Sepsis - Products under Investigation by Universities/Institutes
27 Sepsis - Companies Involved in Therapeutics Development
29 Adrenomed AG
29 Altor BioScience Corporation
30 Am-Pharma B.V.
31 Arch Biopartners, Inc.
32 Asahi Kasei Pharma Corp.
33 Biomedica Management Corporation
34 Cell2B S.A.
35 Chiesi Farmaceutici SpA
36 Chiome Bioscience, Inc.
37 Cilian AG
38 Cognosci, Inc.
39 Diomune S.L
40 Endacea, Inc.
41 Evec, Inc.
42 Huons Co., Ltd.
43 Immune Response BioPharma, Inc.
44 Immunethep, SA
45 ImmunNovative Developments SL
46 InflaRx GmbH
47 Integrated BioTherapeutics, Inc.
48 ISU ABXIS Co.,Ltd.
49 Lead Discovery Center GmbH
50 Navigen Pharmaceuticals, Inc.
51 Novadiscovery SAS
52 Ocata Therapeutics, Inc.
53 OncoImmune, Inc.
54 Opsona Therapeutics Limited
55 ProThera Biologics, LLC.
56 Ribomic Inc.
57 Silence Therapeutics Plc
58 Stemedica Cell Technologies, Inc.
59 Syntiron LLC
60 Takeda Pharmaceutical Company Limited
61 TiGenix NV
62 VBS Pharmaceuticals
63 XImmune AB
64 Sepsis - Therapeutics Assessment
65 Assessment by Monotherapy Products
65 Assessment by Target
66 Assessment by Mechanism of Action
68 Assessment by Route of Administration
70 Assessment by Molecule Type
72 Drug Profiles
74 3K3A-APC - Drug Profile
74 7-H9 - Drug Profile
76 AB-022 - Drug Profile
78 AcPepA - Drug Profile
79 adrecizumab - Drug Profile
80 Alpha B Crystalline - Drug Profile
81 ALT-836 - Drug Profile
82 AM/AMBP-1 - Drug Profile
84 Aspidasept - Drug Profile
87 Atu-111 - Drug Profile
88 bacterial sepsis vaccine - Drug Profile
89 BaxB-01 - Drug Profile
90 BaxG-03 - Drug Profile
91 BaxM-159 - Drug Profile
92 BRL-44408 - Drug Profile
93 BTZO-2 - Drug Profile
95 CAR Peptide - Drug Profile
96 ceftaroline fosamil - Drug Profile
97 CN-16 - Drug Profile
99 COG-133 - Drug Profile
100 Cx-611 - Drug Profile
102 Drug for Sepsis - Drug Profile
104 Drugs for Sepsis - Drug Profile
105 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
106 Drugs to Inhibit Sialidase for Sepsis - Drug Profile
107 Escherichia coli vaccine - Drug Profile
156 - Drug Profile
109 Glyco-23 - Drug Profile
110 HBN-1 - Drug Profile
111 HBN-3 - Drug Profile
112 HBN-4 - Drug Profile
113 HU-003 - Drug Profile
114 IFX-1 - Drug Profile
115 ImmStem - Drug Profile
116 ImmuneSafe - Drug Profile
117 IND-005 - Drug Profile
119 IND-006 - Drug Profile
120 IR-999 - Drug Profile
121 ISU-201 - Drug Profile
122 Klebsiella pneumoniae vaccine - Drug Profile
123 L-97-1 - Drug Profile
124 LB-1148 - Drug Profile
126 LR-17 - Drug Profile
127 M-33 - Drug Profile
128 meropenem - Drug Profile
129 Mesenchymal Stem Cells - Drug Profile
130 Metablok - Drug Profile 132 Micselon - Drug Profile
133 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
134 Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
135 Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
136 Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile
137 Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile
138 Nanotherapeutics - Drug Profile
140 NAV-838 - Drug Profile
141 OPN-305 - Drug Profile
143 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile
145 Polysaccharide for Sepsis - Drug Profile
147 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
148 RBM-005 - Drug Profile
149 Recombinant Enzyme to Replace Alkaline Phosphatase for Sepsis - Drug Profile
150 Recombinant Human Alkaline Phosphatase - Drug Profile
151 Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile
152 Recombinant Protein for Sepsis - Drug Profile
153 Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile
154 Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile
155 SAN-101 - Drug Profile
156 Slit2N - Drug Profile
157 Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile
159 Small Molecule to Inhibit DDAH1 for Sepsis - Drug Profile
160 Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile
161 Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
162 staphylococcus aureus (bivalent) vaccine - Drug Profile
163 Stem Cell Therapy for Autoimmune Diseases - Drug Profile
164 Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases - Drug Profile
165 Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile
166 Synthetic Peptides for Infectious Disease - Drug Profile
167 Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
168 Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile
169 Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections - Drug Profile
170 TF-0003 - Drug Profile
171 thrombomodulin alfa - Drug Profile
172 TRX-306 - Drug Profile
174 vancomycin hydrochloride - Drug Profile
175 Yersinia pestis vaccine - Drug Profile
176 Sepsis - Recent Pipeline Updates
177 Sepsis - Dormant Projects
188 Sepsis - Discontinued Products
192 Sepsis - Product Development Milestones
193 Featured News & Press Releases
198 Secondary Research
198 Primary Research
198 Expert Panel Validation
198 Contact Us
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.